Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
07/2000
07/26/2000EP1021436A1 ETHYL 4-(8-CHLORO-5, 6-DIHYDRO-11H- BENZO 5,6]CYCLOHEPTA 1,2-b]PYRIDIN -11-YLIDENE)-1- PIPERIDENE CARBOXYLATE POLYMORPH
07/26/2000EP1021430A1 Furan nitrone compounds
07/26/2000EP1021413A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
07/26/2000EP1021406A1 Novel anandamide amidase inhibitors as analgesic agents
07/26/2000EP1021202A1 Immunogenic peptides from the hpv e7 protein
07/26/2000EP1021196A2 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
07/26/2000EP1021193A1 THERAPEUTICALLY EFFECTIVE 1$g(a), 25-DIHYDROXYVITAMIN D 3? ANALOGS
07/26/2000EP1021190A1 Novel amide derivatives
07/26/2000EP1021181A1 Carboxylic acid indole inhibitors of chemokines
07/26/2000EP0832134B1 Anti-allergy bispecific molecules
07/26/2000EP0769054B1 Immunomodulators
07/26/2000EP0759775B1 Ifn-beta liquid formulations
07/26/2000CN1261367A Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents
07/26/2000CN1261365A Crystalline macrolides and process for their preparation
07/26/2000CN1261286A CD154 blockade therapy for pancreatin islet tissue transplantation
07/26/2000CN1261285A CD 154 blockade therapy for therapeutic protein inhibitor syndrome
07/26/2000CN1261284A Use of a CD40 : CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
07/26/2000CN1261283A Multivalent in ovo avian vaccine
07/26/2000CN1261277A Novel substituted imidazole compounds
07/26/2000CN1054856C New 19-nor steroids having phenoxyalkylsulphonemide or phenoxyalkylsulphonylurea chain in position llbeta, preparation process and intermediates, use as medicaments and pharmaceutical
07/26/2000CN1054845C Quinoline compounds, their preparing methods and medicinal compositions
07/25/2000US6093838 Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
07/25/2000US6093723 An immunomodulator for treating and preventing immune disorders, including autoimmune disease, inflammatory disease, organ transplant rejection and other disorders associated with il-2 mediated immune response
07/25/2000US6093716 Substituted 2-pyrimidineamines and processes for their preparation
07/25/2000US6093699 Method for gene therapy involving suppression of an immune response
07/25/2000US6093693 B cell activation
07/25/2000US6093561 Human lysophospholipase
07/25/2000US6093532 Method for storing a biological organ transplant graft using a benzisoselen-azoline or -azine compound
07/25/2000US6093405 Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines
07/25/2000CA2197086C (azetidin-1-ylalkyl)lactams as tachykinin antagonists
07/20/2000WO2000042429A2 In vitro model for gastrointestinal inflammation
07/20/2000WO2000042213A1 A novel method for designing protein kinase inhibitors
07/20/2000WO2000042201A2 Human peptidases
07/20/2000WO2000042179A2 Complex-forming proteins
07/20/2000WO2000042172A2 Human homologues of proteins regulated by circadian rhythms
07/20/2000WO2000042168A2 Bifidobacterium in the treatment of inflammatory disease
07/20/2000WO2000042073A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
07/20/2000WO2000042072A2 Polypeptide variants with altered effector function
07/20/2000WO2000042071A2 Compounds and methods to inhibit or augment an inflammatory response
07/20/2000WO2000042054A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000WO2000042053A1 Derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000WO2000042035A1 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
07/20/2000WO2000042029A1 1-heterocycle substituted diarylamines
07/20/2000WO2000042022A1 Benzoheterocycles and their use as mek inhibitors
07/20/2000WO2000042020A1 Phenylphenanthridines with pde-iv inhibiting activity
07/20/2000WO2000042019A1 6-arylphenanthridines with pde-iv inhibiting activity
07/20/2000WO2000042018A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
07/20/2000WO2000042013A1 Cinnamamide derivatives and drug compositions containing the same
07/20/2000WO2000042009A1 Stable activated novel carbamic acid derivatives, preparation method and use for preparing urea
07/20/2000WO2000042003A1 Benzenesulfonamide derivatives and their use as mek inhibitors
07/20/2000WO2000042002A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
07/20/2000WO2000041994A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
07/20/2000WO2000041727A1 Transcutaneous photodynamic treatment of targeted cells
07/20/2000WO2000041724A1 Modulation of systemic memory t cell trafficking
07/20/2000WO2000041721A1 Process for purifying immunoglobulins
07/20/2000WO2000041720A1 Improved saponin adjuvant compositions and methods relating thereto
07/20/2000WO2000041718A1 Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma
07/20/2000WO2000041716A1 New use of melagatran
07/20/2000WO2000041707A2 USE OF $i(LACTOBACILLUS SALIVARIUS)
07/20/2000WO2000041705A1 Pre-conditioning against cell death
07/20/2000WO2000041703A1 Administration of an anti-endotoxin drug by intravenous infusion
07/20/2000WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins
07/20/2000WO2000041547A2 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
07/20/2000WO2000041508A2 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
07/20/2000WO2000041505A2 Anthranilic acid derivatives
07/20/2000WO2000041497A2 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
07/20/2000WO2000041474A2 Anti-cd3 immunotoxins and therapeutic uses therefor
07/20/2000WO2000028943A3 Selection and uses of lactic acid bacteria strains modulating non-specific immunity
07/20/2000WO2000021979A3 Cyclic tetrapeptide and their use as histone deacetylase inhibitor
07/20/2000WO2000020590A3 G-protein coupled receptor proteins
07/20/2000WO2000017358A3 Human chaperone proteins
07/20/2000WO2000004917A3 USE OF HC gp-39 IN IMMUNE DISEASES
07/20/2000CA2724287A1 Bifidobacterium in the treatment of inflammatory disease
07/20/2000CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response
07/20/2000CA2660344A1 Improved saponin adjuvant compositions and methods relating thereto
07/20/2000CA2360588A1 Human homologues of proteins regulated by circadian rhythms
07/20/2000CA2360581A1 A novel method for designing protein kinase inhibitors
07/20/2000CA2360464A1 Human peptidases
07/20/2000CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
07/20/2000CA2360268A1 Pre-conditioning against cell death
07/20/2000CA2360243A1 Use of lactobacillus salivarius
07/20/2000CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000CA2359479A1 Novel complex-forming proteins
07/20/2000CA2359478A1 Administration of an anti-endotoxin drug by intravenous infusion
07/20/2000CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity
07/20/2000CA2359392A1 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
07/20/2000CA2359365A1 Anti-cd3 immunotoxins and therapeutic uses therefor
07/20/2000CA2359111A1 Improved saponin adjuvant compositions and methods relating thereto
07/20/2000CA2359067A1 Polypeptide variants with altered effector function
07/20/2000CA2358684A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
07/20/2000CA2356939A1 Modulation of systemic memory t cell trafficking
07/20/2000CA2356776A1 Transcutaneous photodynamic treatment of targeted cells
07/20/2000CA2356611A1 New use of melagatran
07/20/2000CA2355374A1 1-heterocycle substituted diarylamines
07/20/2000CA2352509A1 Cinnamamide derivatives and pharmaceutical compositions containing the same
07/20/2000CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors
07/20/2000CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
07/20/2000CA2349180A1 Anthranilic acid derivatives
07/20/2000CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
1 ... 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 ... 1172